Finance
Unilever will not raise rejected 50 billion pound bid for GSK consumer arm
Published by maria gbaf
Posted on January 20, 2022
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by maria gbaf
Posted on January 20, 2022
(Reuters) -Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline’s consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.
U.S.-listed shares of Unilever rose 10.1% on the news, while GSK’s fell 2.8% . The two stocks also trade on the FTSE, where the day’s trading had closed.
GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids “fundamentally undervalued” the business and its prospects.
It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.
Unilever said in a statement it had noted these but “determined that it does not change our view on fundamental value. Accordingly, we will not increase our offer above £50 bln”.
A spokesperson for GSK responded that the firm, in which U.S. drugs company Pfizer owns a 32% stake, was strongly focused on maximising shareholder value and very confident in the future of the business and its potential.
“The Consumer Healthcare business has an exceptional portfolio and offers existing and prospective shareholders a highly attractive financial profile supporting investment and future returns,” they added.
In a statement rebuffing Unilever’s overtures last weekend, GSK said the bid failed to capture the unit’s potential, releasing new forecasts that projected annual organic sales growth of 4%-6% for the business, which made sales of 9.6 billion pounds last year, over the medium term.
This estimate was above its prior forecast of seeking to beat the consumer health market’s growth of about 4%.
The British drug maker said it intends to further share details of its strategy for the consumer brands unit at an investor day on 28 February.
The event would follow its fourth-quarter results on 9 February where it might also throw some light on its thinking.
Unilever’s decision not to raise its bid comes after analysts and investors widely panned its offer, sending shares in the maker of Dove soap down 8% on Monday, on worries about the financial implications for the company.
A source familiar with Pfizer’s strategy told Reuters earlier this week that GSK and Pfizer would open negotiations with Unilever’s boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds.
($1 = 0.7337 pounds)
(Reporting by Siddharth Cavale, Aby Jose Koilparambil in Bengaluru and Ludwig Burger in Frankfurt; Editing by Devika Syamnath, Alexandra Hudson)
(Reuters) -Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline’s consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.
U.S.-listed shares of Unilever rose 10.1% on the news, while GSK’s fell 2.8% . The two stocks also trade on the FTSE, where the day’s trading had closed.
GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids “fundamentally undervalued” the business and its prospects.
It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.
Unilever said in a statement it had noted these but “determined that it does not change our view on fundamental value. Accordingly, we will not increase our offer above £50 bln”.
A spokesperson for GSK responded that the firm, in which U.S. drugs company Pfizer owns a 32% stake, was strongly focused on maximising shareholder value and very confident in the future of the business and its potential.
“The Consumer Healthcare business has an exceptional portfolio and offers existing and prospective shareholders a highly attractive financial profile supporting investment and future returns,” they added.
In a statement rebuffing Unilever’s overtures last weekend, GSK said the bid failed to capture the unit’s potential, releasing new forecasts that projected annual organic sales growth of 4%-6% for the business, which made sales of 9.6 billion pounds last year, over the medium term.
This estimate was above its prior forecast of seeking to beat the consumer health market’s growth of about 4%.
The British drug maker said it intends to further share details of its strategy for the consumer brands unit at an investor day on 28 February.
The event would follow its fourth-quarter results on 9 February where it might also throw some light on its thinking.
Unilever’s decision not to raise its bid comes after analysts and investors widely panned its offer, sending shares in the maker of Dove soap down 8% on Monday, on worries about the financial implications for the company.
A source familiar with Pfizer’s strategy told Reuters earlier this week that GSK and Pfizer would open negotiations with Unilever’s boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds.
($1 = 0.7337 pounds)
(Reporting by Siddharth Cavale, Aby Jose Koilparambil in Bengaluru and Ludwig Burger in Frankfurt; Editing by Devika Syamnath, Alexandra Hudson)